Paris, France – 23 September 2010 – DBV Technologies (DBV), a biotechnology company specializing in innovative products for the diagnosis and the treatment of food allergies, announced today that its unique VIASKIN® delivery system has been granted two US patents. In both cases, the lifetime of the patent has been extended until 2026.
Aspects of both patents (US 7,635,488 and US 7,722,897) are incorporated into DBV Technologies’ VIASKIN which delivers allergens compounds to the immune system though intact skin.
DBV Technologies’ VIASKIN is the first device especially developed for EPicutaneous ImmunoTherapy (EPIT). VIASKIN enhances hydration of the surface of the skin and allows the diffusion of allergens into the superficial layers, so that they can interact with the skin’s immune network in order to desensitize food allergy patients safely without any risk of systemic reactions. VIASKIN is applied on intact skin and is completely non-invasive.
Commenting on the announcement, DBV Technologies’ CEO and Co-Founder, Pierre-Henri Benhamou, MD said: “We are delighted to have secured two patents central to our VIASKIN technology, which further strengthen the competitiveness of our core technology and we are delighted this protection has been granted for an extended period. To date VIASKIN is successfully marketed as a diagnostic product but has also shown huge promise as a safe, painless and effective therapy for food allergy desensitization.”
DBV Technologies recently announced that its lead product VIASKIN PEANUT has been selected to be evaluated in a Phase II study of peanut allergy desensitization led by the U.S. Consortium of Food Allergy Research (CoFAR) and funded by the National Institutes of Health (NIH).
More information on the US Patents can be found at:
Patent US 7,635,488 (concerned with ‘Patches and uses thereof’)
Patent US 7,722,897 (concerned with ‘Patch for screening and sensitization state of a subject with respect to an allergen and use thereof’)
More information about DBV Technologies’ Peanut Specific EPIT program can be found at: http://www.dbv-technologies.com/viaskin-peanut.asp
For more information contact:
Media: College Hill Life Sciences
Katja Toon and Tim Watson
Tel: 0044 (0)20 7866 7861
Corporate: DBV Technologies
CEO and Founder
Tel: +33 (0)1 5542 7878
About DBV Technologies - www.dbv-technologies.com
DBV Technologies is a private French company focused on the development of innovative products for the diagnosis and treatment of food allergies. The Company was born out of the experience of Professor Christophe Dupont, a paediatric gastroenterologist, from Assistance Publique-Hôpitaux de Paris and Université Paris Descartes, Doctor Pierre-Henri Benhamou (CEO), a paediatrician specialising in gastro-enterology, allergy and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Métiers Institute. DBV Technologies was founded in 2002 and is based in the Pépinière Paris Santé Cochin, in Paris’ 14th arrondissement.
About DBV Technologies’ Peanut Specific EPIT program
Through its Peanut Specific EPIT program, DBV Technologies aims to safely desensitize patients suffering from peanut allergy, i.e. increase the amount of peanuts that patients can consume symptom-free. Early July 2010, DBV Technologies announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application of its lead food allergy desensitization candidate, VIASKIN PEANUT, for the desensitization to peanut allergy. The U.S. Medical Centres participating in the first-in-man clinical trial are: Duke University Medical Center, Durham, NC; The National Jewish Medical & Research Center, Denver, CO; Arkansas Children’s Hospital Research Institute, Little Rock, AR, Aspen CR, Orem, UT; and CRI Worldwide, Willingboro, NJ.
According to the American Academy of Allergy Asthma & Immunology statistics, peanut allergy is one of the most prevalent food allergies in the U.S. with over 2 million people suffering from this allergy. In the U.S. alone, food allergies are responsible for about 125,000 emergency room visits and 150-200 deaths per year, fatal food anaphylaxis being most often caused by peanuts. Due to the potentially fatal consequences of peanut allergy, this condition represents a major health concern worldwide and imposes severe social and quality of life restrictions on afflicted individuals.
DBV Technologies has already published strong pre-clinical data supporting its peanut allergy EPIT program. These are available for review on the Scientific Publications page on the DBV Technologies website. To date, no food allergy desensitization treatment is currently marketed for the treatment of food allergies such as peanut allergy.
More information about DBV Technologies’ Peanut Allergy EPIT trials is available at:
DBV Technologies’ patented VIASKIN® technology is a unique delivery system which retains active compounds on a carrier using electrostatic forces only. The delivery platform allows active compounds to be presented to the epidermis of the skin without breaking the blood-skin barrier. In not breaking the blood-skin barrier, DBV Technologies’ allergen diagnosis and Epicutaneous specific ImmunoTherapy (EPIT) should avoid inducing systemic shock – one of the most serious concerns associated with current desensitization therapies.
More information about DBV Technologies’ VIASKIN technology can be found at:
This email, its content and any files transmitted with it are confidential and are intended only for the addressee. If you are not the addressee, you may not print, copy, use or rely on the contents, attachments or information in any way except with the express written permission of the sender. If this email has been sent to you in error please destroy it and contact the sender. This email has been prepared using information believed by the author to be reliable and accurate, but College Hill makes no warranty as to its accuracy or completeness.
In particular, College Hill does not accept changes made to this email after it was sent.
Company Name: College Hill Ltd, Company Number: 1036926
Registered Address: The Registry, Royal Mint Court, London EC3N 4QN UK